Instrument Inactif

Autres langues Bio Vitos Pharma

Actions

BIOVIT

SE0023286919

Equipement, fournitures et distribution médicale

Autres langues

25/03/25	Alerts on Bio Vitos Pharma withdrawn
28/02/25	Bio Vitos Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024
15/11/24	Bio Vitos Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
13/11/24	Bio Vitos Pharma AB (publ) appoints LAGO KAPITAL as liquidity provider
30/08/24	Bio Vitos Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
13/05/24	Bio Vitos Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
14/02/24	Bio Vitos Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023
14/02/24	Bio Vitos Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
12/02/24	Bio Vitos Pharma Teams Up with KFUM Kalmar to Explore Benefits of Iron Succinate for Female Athletes
12/02/24	KFUM Kalmar and Bio Vitos Pharma enter into an agreement regarding a research study on Succifer
12/02/24	KFUM Kalmar and Bio Vitos Pharma Sign Collaboration Agreement to Conduct Research Study on Succifer
20/12/23	The European Patent Office EPO grants patent that is important to Bio Vitos Pharma
20/12/23	The European Patent Office EPO Grants Patent to Bio Vitos Pharma AB
06/12/23	Hemcheck Sweden AB will Change its Ticker to BIOVIT from HEMC
06/12/23	Hemcheck Sweden AB will Change its Name to Bio Vitos Pharma AB
16/11/23	Bio Vitos Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
20/10/23	Hemcheck completes the transaction with Bio Vitos
30/08/23	Bio Vitos Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
15/05/23	Hemcheck has received a first order from its distributor Astemed
15/05/23	Hemcheck Sweden AB Receives A First Order from Its Distributor Astemed
09/05/23	Hemcheck Sweden AB Reports Earnings Results for the First Quarter Ended March 31, 2023
04/05/23	Hemcheck submits a formal application to Nasdaq for a decision on continued listing before the implementation of the Bio Vitos agreement
26/04/23	Additional follow up order from the Foundation for Innovative New Diagnostics (FIND)
26/04/23	Hemcheck Sweden Receives New Follow Up Order from the Foundation for Innovative New Diagnostics
05/04/23	Hemcheck has received a first order from the university hospital Charité in Berlin